Stockscreener 앱 받기
1.12
9.68%
-0.12
시간 외 거래:
1.15
0.03
+2.68%
전일 마감가:
$1.24
열려 있는:
$1.17
하루 거래량:
1.47M
Relative Volume:
2.87
시가총액:
$58.77M
수익:
$21.05M
순이익/손실:
$-89.22M
주가수익비율:
-0.6257
EPS:
-1.79
순현금흐름:
$-64.50M
1주 성능:
-47.42%
1개월 성능:
-46.92%
6개월 성능:
-30.00%
1년 성능:
-77.95%
1일 변동 폭
$1.08
$1.25
1주일 범위
$1.08
$2.14
52주 변동 폭
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
명칭
Tscan Therapeutics Inc
전화
857-399-9500
주소
830 WINTER STREET, WALTHAM
TCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.12 | 70.37M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-16 | 개시 | BTIG Research | Buy |
| 2024-05-13 | 개시 | Needham | Buy |
| 2023-06-22 | 개시 | Wedbush | Outperform |
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
TScan Therapeutics Shares Fall After BTIG Research Downgrade - MarketScreener
Biotech firm TScan slashes jobs, extends cash runway amid strategic realignment - The Business Journals
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays By Investing.com - Investing.com Australia
BTIG Research Downgrades TScan Therapeutics to Neutral From Buy - MarketScreener
Needham Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays - Investing.com
TScan Therapeutics (TCRX) Analyst Update: Needham Lowers Price T - GuruFocus
Reversal indicators forming on TScan Therapeutics Inc. stockQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.Earnings Growth Report & Precise Swing Trade Entry Alerts - newser.com
Best data tools to analyze TScan Therapeutics Inc. stockDollar Strength & Reliable Intraday Trade Alerts - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Winners & Losers & Fast Entry High Yield Tips - newser.com
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com Nigeria
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com UK
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
Trend analysis for TScan Therapeutics Inc. this weekWatch List & Target Return Focused Picks - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesRecession Risk & Low Risk Entry Point Tips - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comebackExit Point & Weekly Watchlist of Top Performers - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.Weekly Risk Report & High Yield Equity Trading Tips - newser.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - TipRanks
TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
TScan Therapeutics expects $2.3 million one-time charge for severance during 3 months ended Dec 31 - MarketScreener
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
TScan Therapeutics (NASDAQ: TCRX) extends cash runway to H2 2027; cuts workforce about 30% - Stock Titan
Technical signs of recovery in TScan Therapeutics Inc.Chart Signals & Stock Timing and Entry Methods - newser.com
Should you wait for a breakout in TScan Therapeutics Inc.Portfolio Risk Summary & Community Driven Trade Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economy2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Is TScan Therapeutics Inc. building a consolidation base2025 Year in Review & Stock Timing and Entry Methods - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryEarnings Growth Report & Community Trade Idea Sharing - newser.com
Is TScan Therapeutics Inc. still worth holding after the dipBull Run & Technical Pattern Recognition Alerts - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Weekly Trade Recap & AI Based Buy/Sell Signal Reports - newser.com
Tscan Therapeutics Inc (TCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):